These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 34747718)

  • 1. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.
    Zhang W; Zhang L; Jiang H; Li Y; Wang S; Wang Q
    Aging (Albany NY); 2021 Nov; 13(21):24136-24154. PubMed ID: 34747718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The complementarity of DDR, nucleic acids and anti-tumour immunity.
    Kornepati AVR; Rogers CM; Sung P; Curiel TJ
    Nature; 2023 Jul; 619(7970):475-486. PubMed ID: 37468584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.
    Wang Y; Jiao X; Li S; Chen H; Wei X; Liu C; Gong J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Wang Y; Zhuo N; Zou J; Zhang H; Li J; Shen L; Lu Z
    Cancer Biol Med; 2021 Sep; 19(8):1139-49. PubMed ID: 34570439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.
    Vidotto T; Nersesian S; Graham C; Siemens DR; Koti M
    J Immunother Cancer; 2019 Jun; 7(1):148. PubMed ID: 31174611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment.
    Xu P; Gao Y; Jiang S; Cui Y; Xie Y; Kang Z; Chen YX; Sun D; Fang JY
    Cancer Lett; 2024 Apr; 588():216595. PubMed ID: 38097135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
    Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
    Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer.
    Zhou Y; Tan Y; Zhang Q; Duan Q; Chen J
    Eur J Med Res; 2022 Oct; 27(1):225. PubMed ID: 36309740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.
    Zhu L; Liu J; Chen J; Zhou Q
    J Hematol Oncol; 2021 Dec; 14(1):206. PubMed ID: 34930377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response.
    Weir WH; Mucha PJ; Kim WY
    Cell Rep Med; 2022 May; 3(5):100602. PubMed ID: 35584624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
    Huang JL; Chang YT; Hong ZY; Lin CS
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.
    Zhou C; Lin A; Cao M; Ding W; Mou W; Guo N; Chen Z; Zhang J; Luo P
    Front Immunol; 2021; 12():634741. PubMed ID: 34220801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
    Song Y; Huang J; Liang D; Hu Y; Mao B; Li Q; Sun H; Yang Y; Zhang J; Zhang H; Chen H; Liu H; Zhang S
    Front Oncol; 2020; 10():549777. PubMed ID: 33680909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
    Shi C; Qin K; Lin A; Jiang A; Cheng Q; Liu Z; Zhang J; Luo P
    J Exp Clin Cancer Res; 2022 Sep; 41(1):268. PubMed ID: 36071479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
    Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
    Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
    Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
    Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
    Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
    BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.